The purpose of this study is to see if it is safe to give amprenavir (APV) to HIV-infected
patients. This study also examines the effect APV has on the level of HIV in the blood.
Earlier studies have shown that APV is effective in slowing the growth of HIV in the body.
Patients who have failed previous anti-HIV treatment or who are unable to take other protease
inhibitors (PIs) may benefit from the availability of a new PI such as APV.
Phase:
N/A
Details
Lead Sponsor:
Glaxo Wellcome
Treatments:
Amprenavir HIV Protease Inhibitors Protease Inhibitors